Ketone-selenoesters as potential anticancer and multidrug resistance modulation agents in 2D and 3D ovarian and breast cancer in vitro models.


Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
21 04 2022
Historique:
received: 25 11 2021
accepted: 11 03 2022
entrez: 22 4 2022
pubmed: 23 4 2022
medline: 26 4 2022
Statut: epublish

Résumé

Long-term treatment of cancer with chemotherapeutics leads to the development of resistant forms that reduce treatment options. The main associated mechanism is the overexpression of transport proteins, particularly P-glycoprotein (P-gp, ABCB1). In this study, we have tested the anticancer and multidrug resistance (MDR) modulation activity of 15 selenocompounds. Out of the tested compounds, K3, K4, and K7 achieved the highest sensitization rate in ovarian carcinoma cells (HOC/ADR) that are resistant to the action of the Adriamycin. These compounds induced oxidation stress, inhibited P-gp transport activity and altered ABC gene expression. To verify the effect of compounds, 3D cell models were used to better mimic in vivo conditions. K4 and K7 triggered the most significant ROS release. All selected selenoesters inhibited P-gp efflux in a dose-dependent manner while simultaneously altering the expression of the ABC genes, especially P-gp in paclitaxel-resistant breast carcinoma cells (MCF-7/PAX). K4, and K7 demonstrated sensitization potential in resistant ovarian spheroids. Additionally, all selected selenoesters achieved a high cytotoxic effect in 3D breast and ovarian models, which was comparable to that in 2D cultures. K7 was the only non-competitive P-gp inhibitor, and therefore appears to have considerable potential for the treatment of drug-resistant cancer.

Identifiants

pubmed: 35449387
doi: 10.1038/s41598-022-10311-y
pii: 10.1038/s41598-022-10311-y
pmc: PMC9023544
doi:

Substances chimiques

Antineoplastic Agents 0
Ketones 0
Doxorubicin 80168379AG

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

6548

Informations de copyright

© 2022. The Author(s).

Références

Med Res Rev. 2017 Sep;37(5):987-1050
pubmed: 28005280
Oncotarget. 2017 Jul 12;8(48):84559-84571
pubmed: 29137448
FASEB J. 2004 Jul;18(10):1129-31
pubmed: 15155565
Biomed Pharmacother. 2021 Jul;139:111632
pubmed: 34243600
Bioorg Med Chem Lett. 2016 Jun 15;26(12):2821-2824
pubmed: 27156771
Molecules. 2014 Aug 25;19(9):13061-75
pubmed: 25157469
Drug Resist Updat. 2015 Jan;18:1-17
pubmed: 25554624
Clin Cancer Res. 2008 Mar 1;14(5):1310-6
pubmed: 18316549
Oxid Med Cell Longev. 2019 Dec 18;2019:5381692
pubmed: 31929855
J Med Chem. 2010 Oct 14;53(19):6954-63
pubmed: 20836556
Biochem J. 2010 Jul 1;429(1):85-93
pubmed: 20408818
Int J Mol Sci. 2019 Jun 19;20(12):
pubmed: 31248089
Hum Genomics. 2009 Apr;3(3):281-90
pubmed: 19403462
Trends Pharmacol Sci. 2004 Aug;25(8):423-9
pubmed: 15276711
Front Oncol. 2020 Jan 17;9:1541
pubmed: 32010628
Biochem Biophys Res Commun. 2011 May 20;408(4):713-9
pubmed: 21549092
Clin Chem. 2009 Apr;55(4):611-22
pubmed: 19246619
Toxicol Appl Pharmacol. 2016 Nov 1;310:215-228
pubmed: 27664577
Br J Pharmacol. 2014 Dec;171(24):5845-57
pubmed: 25164592
Biomed Pharmacother. 2014 Mar;68(2):179-83
pubmed: 24184201
Cancers (Basel). 2018 Dec 04;10(12):
pubmed: 30518036
Antioxidants (Basel). 2020 May 25;9(5):
pubmed: 32466263
Biochim Biophys Acta. 2015 Aug;1850(8):1642-60
pubmed: 25459512
Bioorg Med Chem Lett. 2017 Feb 15;27(4):797-802
pubmed: 28126516
CA Cancer J Clin. 2021 May;71(3):209-249
pubmed: 33538338
Int J Mol Sci. 2015 Mar 11;16(3):5517-27
pubmed: 25768338
Cell Death Dis. 2021 Apr 1;12(4):339
pubmed: 33795647
Adv Exp Med Biol. 2007;608:1-22
pubmed: 17993229
Antioxidants (Basel). 2019 Aug 14;8(8):
pubmed: 31416138
J Agric Food Chem. 2020 Feb 19;68(7):1763-1779
pubmed: 30907588
Curr Med Chem. 2012;19(13):1946-2025
pubmed: 22257057
Life Sci. 2018 Dec 1;214:118-123
pubmed: 30449449
World J Stem Cells. 2019 Dec 26;11(12):1065-1083
pubmed: 31875869
Foods. 2020 May 05;9(5):
pubmed: 32380674
Drug Resist Updat. 2012 Feb-Apr;15(1-2):98-105
pubmed: 22483810
Metallomics. 2019 Mar 20;11(3):666-675
pubmed: 30839008
Antioxid Redox Signal. 2007 Jul;9(7):775-806
pubmed: 17508906
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
Oncologist. 2012;17(4):512
pubmed: 22416063
Cancer Biol Ther. 2015;16(1):106-14
pubmed: 25482933
J Biol Chem. 2014 Nov 7;289(45):30880-8
pubmed: 25281745
Adv Cancer Res. 2017;136:259-302
pubmed: 29054421
Invest New Drugs. 2012 Dec;30(6):2364-70
pubmed: 22331549
Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):52-60
pubmed: 30268729
Gen Physiol Biophys. 2001 Sep;20(3):215-37
pubmed: 11765214
Cancers (Basel). 2021 Sep 11;13(18):
pubmed: 34572790
Biochim Biophys Acta. 1976 Nov 11;455(1):152-62
pubmed: 990323
Arch Toxicol. 2010 Dec;84(12):919-38
pubmed: 20871980
ACS Chem Neurosci. 2011 Feb 16;2(2):82-9
pubmed: 22778859
J Chromatogr B Analyt Technol Biomed Life Sci. 2016 Apr 15;1019:29-44
pubmed: 26922696
Anticancer Res. 2019 Jul;39(7):3777-3783
pubmed: 31262904
Nutrients. 2015 May 13;7(5):3536-56
pubmed: 25984742
Molecules. 2019 Jan 18;24(2):
pubmed: 30669343

Auteurs

Simona Dobiasová (S)

Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 3, 166 28, Prague 6, Czechia.

Nikoletta Szemerédi (N)

Department of Medical Microbiology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, Szeged, 6725, Hungary.

Denisa Kučerová (D)

Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 3, 166 28, Prague 6, Czechia.

Kamila Koucká (K)

Toxicogenomics Unit, National Institute of Public Health, Šrobárova 49, 100 00, Prague, Czechia.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00, Pilsen, Czechia.

Radka Václavíková (R)

Toxicogenomics Unit, National Institute of Public Health, Šrobárova 49, 100 00, Prague, Czechia.
Laboratory of Pharmacogenomics, Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 1655, 323 00, Pilsen, Czechia.

Helena Gbelcová (H)

Institute of Medical Biology, Genetics and Clinical Genetics, Faculty of Medicine, Comenius University in Bratislava, Sasinkova 4, 811 08, Bratislava, Slovakia.

Tomáš Ruml (T)

Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 3, 166 28, Prague 6, Czechia.

Enrique Domínguez-Álvarez (E)

Instituto de Química Orgánica General (IQOG-CSIC), Consejo Superior de Investigaciones Científicas, Juan de la Cierva 3, 28006, Madrid, Spain. e.dominguez-alvarez@iqog.csic.es.

Gabriella Spengler (G)

Department of Medical Microbiology, Albert Szent-Györgyi Medical School, University of Szeged, Semmelweis utca 6, Szeged, 6725, Hungary. spengler.gabriella@med.u-szeged.hu.

Jitka Viktorová (J)

Department of Biochemistry and Microbiology, Faculty of Food and Biochemical Technology, University of Chemistry and Technology Prague, Technická 3, 166 28, Prague 6, Czechia. prokesoj@vscht.cz.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH